
Opinion|Videos|June 1, 2024
The Evolving Treatment Landscape in BCG-Unresponsive NMIBC
Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5












